Persistence of oral 5-ASA treatment in ulcerative colitis.

Not Applicable

• Conditions: lcerative Colitis

• Registration Number: JPRN-UMIN000048318
• Lead Sponsor: MOCHIDA PHARMACEUTICAL CO., LTD.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-07-08
• Study Completion: 2022-11-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 4400

Inclusion Criteria

Not provided

Exclusion Criteria

1. The following diagnostic or implementation records for 6 months from the previous month of the Index and for the next 13 months including the Index. - Crohn's disease - Colorectal cancer - Total and subtotal resection of the colorectal and colon 2. Oral 5-ASA prescriptions outside the approved dose range for the next 13 months, including Index date. 3. Records of unknown prescription dates for oral 5-ASA and topical preparations in the next 13 months, including the Index date. 4. Prescription with unknown drug name or standards for oral 5-ASA or topical preparations in the next 13 months, including the Index date.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Persistence of oral 5-ASA treatment

Secondary Outcome Measures

Name	Time	Method
1. Medication possession ratio of topical preparation 2. Adherence 3. Factors having an impact on persistence 4. Factors having an impact on adherence